NCT02932280: Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment

NCT02932280
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 6 Years to 21 Years (Child, Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Symptomatic or unstable brain metastases
https://ClinicalTrials.gov/show/NCT02932280

Comments are closed.

Up ↑